S&P 500   3,310.86 (-0.33%)
DOW   29,049.55 (-0.47%)
QQQ   223.56 (-0.14%)
AAPL   317.76 (+0.02%)
FB   219.66 (-0.75%)
MSFT   165.91 (+0.13%)
GOOGL   1,486.14 (+0.13%)
AMZN   1,878.86 (-0.46%)
CGC   24.37 (+0.99%)
NVDA   250.95 (+0.36%)
BABA   217.31 (-2.28%)
MU   59.18 (+0.02%)
GE   11.71 (+2.99%)
TSLA   564.16 (-0.95%)
AMD   51.12 (-0.60%)
T   38.60 (-1.15%)
ACB   2.04 (+0.00%)
F   9.04 (-1.31%)
NFLX   343.42 (+5.34%)
BAC   33.97 (-1.14%)
DIS   141.65 (-1.64%)
GILD   63.14 (-0.46%)
S&P 500   3,310.86 (-0.33%)
DOW   29,049.55 (-0.47%)
QQQ   223.56 (-0.14%)
AAPL   317.76 (+0.02%)
FB   219.66 (-0.75%)
MSFT   165.91 (+0.13%)
GOOGL   1,486.14 (+0.13%)
AMZN   1,878.86 (-0.46%)
CGC   24.37 (+0.99%)
NVDA   250.95 (+0.36%)
BABA   217.31 (-2.28%)
MU   59.18 (+0.02%)
GE   11.71 (+2.99%)
TSLA   564.16 (-0.95%)
AMD   51.12 (-0.60%)
T   38.60 (-1.15%)
ACB   2.04 (+0.00%)
F   9.04 (-1.31%)
NFLX   343.42 (+5.34%)
BAC   33.97 (-1.14%)
DIS   141.65 (-1.64%)
GILD   63.14 (-0.46%)
S&P 500   3,310.86 (-0.33%)
DOW   29,049.55 (-0.47%)
QQQ   223.56 (-0.14%)
AAPL   317.76 (+0.02%)
FB   219.66 (-0.75%)
MSFT   165.91 (+0.13%)
GOOGL   1,486.14 (+0.13%)
AMZN   1,878.86 (-0.46%)
CGC   24.37 (+0.99%)
NVDA   250.95 (+0.36%)
BABA   217.31 (-2.28%)
MU   59.18 (+0.02%)
GE   11.71 (+2.99%)
TSLA   564.16 (-0.95%)
AMD   51.12 (-0.60%)
T   38.60 (-1.15%)
ACB   2.04 (+0.00%)
F   9.04 (-1.31%)
NFLX   343.42 (+5.34%)
BAC   33.97 (-1.14%)
DIS   141.65 (-1.64%)
GILD   63.14 (-0.46%)
S&P 500   3,310.86 (-0.33%)
DOW   29,049.55 (-0.47%)
QQQ   223.56 (-0.14%)
AAPL   317.76 (+0.02%)
FB   219.66 (-0.75%)
MSFT   165.91 (+0.13%)
GOOGL   1,486.14 (+0.13%)
AMZN   1,878.86 (-0.46%)
CGC   24.37 (+0.99%)
NVDA   250.95 (+0.36%)
BABA   217.31 (-2.28%)
MU   59.18 (+0.02%)
GE   11.71 (+2.99%)
TSLA   564.16 (-0.95%)
AMD   51.12 (-0.60%)
T   38.60 (-1.15%)
ACB   2.04 (+0.00%)
F   9.04 (-1.31%)
NFLX   343.42 (+5.34%)
BAC   33.97 (-1.14%)
DIS   141.65 (-1.64%)
GILD   63.14 (-0.46%)
Log in
(Ad)
One of the best ways to double, if not triple your investment in 2020 will be found in tech stocks. Especially those involved with the 5G rollout, where we're still finding undervalued opportunities. In our latest special report, we detail these and other hot tech stocks that should be part of your portfolio right now.

NASDAQ:AMED - Amedisys Stock Price, Forecast & News

$179.61
-1.67 (-0.92 %)
(As of 01/23/2020 01:07 PM ET)
Today's Range
$179.24
Now: $179.61
$181.02
50-Day Range
$160.83
MA: $168.54
$181.32
52-Week Range
$106.65
Now: $179.61
$184.78
Volume2,930 shs
Average Volume181,283 shs
Market Capitalization$5.79 billion
P/E Ratio46.77
Dividend YieldN/A
Beta1.48
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks. Read More…

Industry, Sector and Symbol

Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
Current SymbolNASDAQ:AMED
CUSIP02343610
Phone225-292-2031

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.66 billion
Cash Flow$4.25 per share
Book Value$15.14 per share

Profitability

Net Income$119.35 million

Miscellaneous

Employees21,000
Market Cap$5.79 billion
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive AMED News and Ratings via Email

Sign-up to receive the latest news and ratings for AMED and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

A Jump Trader caught a 58% gain in just ONE DAY...

Another, $2,080 in profit in just ONE DAY...

Every day you miss out on this could be costing you... $500...

$1,000... Even $2,080 a day...

Amedisys (NASDAQ:AMED) Frequently Asked Questions

What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

How were Amedisys' earnings last quarter?

Amedisys Inc (NASDAQ:AMED) announced its quarterly earnings data on Tuesday, October, 29th. The health services provider reported $1.15 EPS for the quarter, beating the consensus estimate of $0.90 by $0.25. The health services provider had revenue of $494.63 million for the quarter, compared to analyst estimates of $494.14 million. Amedisys had a return on equity of 26.53% and a net margin of 6.70%. The company's revenue was up 18.5% on a year-over-year basis. During the same period in the prior year, the company earned $0.95 EPS. View Amedisys' Earnings History.

When is Amedisys' next earnings date?

Amedisys is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Amedisys.

What guidance has Amedisys issued on next quarter's earnings?

Amedisys updated its FY19 earnings guidance on Tuesday, October, 29th. The company provided EPS guidance of $4.32-4.39 for the period, compared to the Thomson Reuters consensus estimate of $4.15. The company issued revenue guidance of $1.94-1.98 billion, compared to the consensus revenue estimate of $1.97 billion.

What price target have analysts set for AMED?

13 equities research analysts have issued 12-month price objectives for Amedisys' shares. Their forecasts range from $124.00 to $206.00. On average, they expect Amedisys' share price to reach $159.62 in the next twelve months. This suggests that the stock has a possible downside of 11.1%. View Analyst Price Targets for Amedisys.

What is the consensus analysts' recommendation for Amedisys?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 5 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amedisys.

Has Amedisys been receiving favorable news coverage?

Press coverage about AMED stock has been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Amedisys earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned news headlines about the health services provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Amedisys.

Who are some of Amedisys' key competitors?

What other stocks do shareholders of Amedisys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include Alibaba Group (BABA), Cisco Systems (CSCO), NVIDIA (NVDA), Verizon Communications (VZ), Netflix (NFLX), QUALCOMM (QCOM), Micron Technology (MU), Adobe (ADBE), Baidu (BIDU) and CVS Health (CVS).

Who are Amedisys' key executives?

Amedisys' management team includes the folowing people:
  • Mr. Paul Berthold Kusserow, Pres, CEO & Director (Age 58)
  • Mr. Scott G. Ginn, Chief Financial Officer (Age 50)
  • Mr. Christopher T. Gerard, Chief Operating Officer (Age 52)
  • Mr. David L. Kemmerly, Sr. VP of Gov. Affairs & Gen. Counsel (Age 56)
  • Ms. Sharon Brunecz, Chief HR Officer (Age 52)

Who are Amedisys' major shareholders?

Amedisys' stock is owned by many different of institutional and retail investors. Top institutional investors include Riverbridge Partners LLC (2.06%), Calamos Advisors LLC (0.13%), Gradient Investments LLC (0.06%), Janney Montgomery Scott LLC (0.03%), Louisiana State Employees Retirement System (0.02%) and State of Alaska Department of Revenue (0.02%). Company insiders that own Amedisys stock include Bruce D Perkins, Christopher Gerard, David B Pearce, David L Kemmerly, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Kkr Credit Advisors (Us) Llc, Linda J Hall, Michael Paul North, Scott G Ginn and Sharon Brunecz. View Institutional Ownership Trends for Amedisys.

Which major investors are selling Amedisys stock?

AMED stock was sold by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Janney Montgomery Scott LLC, State of Alaska Department of Revenue and Calamos Advisors LLC. Company insiders that have sold Amedisys company stock in the last year include Christopher Gerard, David B Pearce, David L Kemmerly, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Michael Paul North, Scott G Ginn and Sharon Brunecz. View Insider Buying and Selling for Amedisys.

Which major investors are buying Amedisys stock?

AMED stock was bought by a variety of institutional investors in the last quarter, including Gradient Investments LLC, NewSquare Capital LLC, HBW Advisory Services LLC, We Are One Seven LLC, Camelot Portfolios LLC, Zurcher Kantonalbank Zurich Cantonalbank , Louisiana State Employees Retirement System and NEXT Financial Group Inc. View Insider Buying and Selling for Amedisys.

How do I buy shares of Amedisys?

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Amedisys' stock price today?

One share of AMED stock can currently be purchased for approximately $179.61.

How big of a company is Amedisys?

Amedisys has a market capitalization of $5.79 billion and generates $1.66 billion in revenue each year. The health services provider earns $119.35 million in net income (profit) each year or $3.63 on an earnings per share basis. Amedisys employs 21,000 workers across the globe.View Additional Information About Amedisys.

What is Amedisys' official website?

The official website for Amedisys is http://www.amedisys.com/.

How can I contact Amedisys?

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]


MarketBeat Community Rating for Amedisys (NASDAQ AMED)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  359 (Vote Outperform)
Underperform Votes:  512 (Vote Underperform)
Total Votes:  871
MarketBeat's community ratings are surveys of what our community members think about Amedisys and other stocks. Vote "Outperform" if you believe AMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel